Obesity drug Saxenda 1-week continuous development, patent application
Peptron (CEO Ho-il Choi) announced on the 18th that it developed an injectable obesity treatment saxenda as a 1-week long-acting formulation and applied for a related technology patent. According to Peptron, the Saxenda Saxenda long-acting formulation uses a drug delivery technology developed in-house to improve the ease of administration from daily injection to once a … Read more